vs

Side-by-side financial comparison of Paranovus Entertainment Technology Ltd. (PAVS) and UTAH MEDICAL PRODUCTS INC (UTMD). Click either name above to swap in a different company.

Paranovus Entertainment Technology Ltd. is the larger business by last-quarter revenue ($12.4M vs $9.0M, roughly 1.4× UTAH MEDICAL PRODUCTS INC). UTAH MEDICAL PRODUCTS INC runs the higher net margin — 28.4% vs -5.5%, a 33.9% gap on every dollar of revenue. On growth, Paranovus Entertainment Technology Ltd. posted the faster year-over-year revenue change (18033.4% vs -1.2%).

Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...

PAVS vs UTMD — Head-to-Head

Bigger by revenue
PAVS
PAVS
1.4× larger
PAVS
$12.4M
$9.0M
UTMD
Growing faster (revenue YoY)
PAVS
PAVS
+18034.6% gap
PAVS
18033.4%
-1.2%
UTMD
Higher net margin
UTMD
UTMD
33.9% more per $
UTMD
28.4%
-5.5%
PAVS

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
PAVS
PAVS
UTMD
UTMD
Revenue
$12.4M
$9.0M
Net Profit
$-681.0K
$2.6M
Gross Margin
20.0%
58.2%
Operating Margin
-5.1%
27.0%
Net Margin
-5.5%
28.4%
Revenue YoY
18033.4%
-1.2%
Net Profit YoY
61.4%
-11.6%
EPS (diluted)
$0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PAVS
PAVS
UTMD
UTMD
Q4 25
$9.0M
Q3 25
$12.4M
$9.8M
Q2 25
$10.0M
Q1 25
$9.7M
Q4 24
$9.2M
Q3 24
$10.0M
Q2 24
$10.4M
Q1 24
$11.3M
Net Profit
PAVS
PAVS
UTMD
UTMD
Q4 25
$2.6M
Q3 25
$-681.0K
$2.6M
Q2 25
$3.0M
Q1 25
$3.0M
Q4 24
$2.9M
Q3 24
$3.6M
Q2 24
$3.5M
Q1 24
$4.0M
Gross Margin
PAVS
PAVS
UTMD
UTMD
Q4 25
58.2%
Q3 25
20.0%
57.1%
Q2 25
56.2%
Q1 25
57.0%
Q4 24
58.1%
Q3 24
58.0%
Q2 24
60.1%
Q1 24
59.7%
Operating Margin
PAVS
PAVS
UTMD
UTMD
Q4 25
27.0%
Q3 25
-5.1%
26.6%
Q2 25
32.1%
Q1 25
32.5%
Q4 24
32.0%
Q3 24
33.4%
Q2 24
33.1%
Q1 24
34.2%
Net Margin
PAVS
PAVS
UTMD
UTMD
Q4 25
28.4%
Q3 25
-5.5%
26.8%
Q2 25
30.6%
Q1 25
31.3%
Q4 24
31.7%
Q3 24
35.6%
Q2 24
33.2%
Q1 24
34.9%
EPS (diluted)
PAVS
PAVS
UTMD
UTMD
Q4 25
$0.80
Q3 25
$0.82
Q2 25
$0.94
Q1 25
$0.92
Q4 24
$0.86
Q3 24
$1.03
Q2 24
$0.98
Q1 24
$1.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PAVS
PAVS
UTMD
UTMD
Cash + ST InvestmentsLiquidity on hand
$5.2M
$85.8M
Total DebtLower is stronger
$225.0K
Stockholders' EquityBook value
$23.6M
$119.3M
Total Assets
$37.3M
$122.5M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PAVS
PAVS
UTMD
UTMD
Q4 25
$85.8M
Q3 25
$5.2M
$84.3M
Q2 25
$82.2M
Q1 25
$83.3M
Q4 24
$83.0M
Q3 24
$88.5M
Q2 24
$89.2M
Q1 24
$93.8M
Total Debt
PAVS
PAVS
UTMD
UTMD
Q4 25
$225.0K
Q3 25
Q2 25
Q1 25
$269.0K
Q4 24
$282.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
PAVS
PAVS
UTMD
UTMD
Q4 25
$119.3M
Q3 25
$23.6M
$118.3M
Q2 25
$117.5M
Q1 25
$117.0M
Q4 24
$117.4M
Q3 24
$124.2M
Q2 24
$124.1M
Q1 24
$127.7M
Total Assets
PAVS
PAVS
UTMD
UTMD
Q4 25
$122.5M
Q3 25
$37.3M
$122.0M
Q2 25
$120.8M
Q1 25
$122.5M
Q4 24
$122.5M
Q3 24
$129.7M
Q2 24
$130.0M
Q1 24
$135.4M
Debt / Equity
PAVS
PAVS
UTMD
UTMD
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
0.00×
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PAVS
PAVS
UTMD
UTMD
Operating Cash FlowLast quarter
$-159.3K
$3.5M
Free Cash FlowOCF − Capex
$3.4M
FCF MarginFCF / Revenue
37.2%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PAVS
PAVS
UTMD
UTMD
Q4 25
$3.5M
Q3 25
$-159.3K
$3.9M
Q2 25
$2.9M
Q1 25
$4.5M
Q4 24
$2.9M
Q3 24
$3.9M
Q2 24
$2.8M
Q1 24
$5.3M
Free Cash Flow
PAVS
PAVS
UTMD
UTMD
Q4 25
$3.4M
Q3 25
$3.9M
Q2 25
$2.8M
Q1 25
$4.3M
Q4 24
$2.9M
Q3 24
$3.8M
Q2 24
$2.7M
Q1 24
$5.3M
FCF Margin
PAVS
PAVS
UTMD
UTMD
Q4 25
37.2%
Q3 25
39.2%
Q2 25
28.4%
Q1 25
44.1%
Q4 24
32.0%
Q3 24
37.7%
Q2 24
25.5%
Q1 24
46.3%
Capex Intensity
PAVS
PAVS
UTMD
UTMD
Q4 25
1.2%
Q3 25
0.3%
Q2 25
0.5%
Q1 25
1.9%
Q4 24
0.1%
Q3 24
0.9%
Q2 24
1.1%
Q1 24
0.2%
Cash Conversion
PAVS
PAVS
UTMD
UTMD
Q4 25
1.36×
Q3 25
1.47×
Q2 25
0.94×
Q1 25
1.47×
Q4 24
1.01×
Q3 24
1.08×
Q2 24
0.80×
Q1 24
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons